Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.
Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L. Hanel W, et al. Among authors: helmig mason j. Exp Hematol Oncol. 2022 Jul 13;11(1):40. doi: 10.1186/s40164-022-00293-y. Exp Hematol Oncol. 2022. PMID: 35831896 Free PMC article.
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L. Youssef Y, et al. Among authors: helmig mason j. Haematologica. 2021 Nov 1;106(11):2927-2939. doi: 10.3324/haematol.2020.268235. Haematologica. 2021. PMID: 33054136 Free PMC article.
Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.
Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L. Choueiry F, et al. Among authors: helmig mason j. Cancers (Basel). 2021 Apr 29;13(9):2146. doi: 10.3390/cancers13092146. Cancers (Basel). 2021. PMID: 33946867 Free PMC article.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: helmig mason j. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason J, Long M, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, Di Liberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA. Brown-Burke F, et al. Among authors: helmig mason j. Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906. Blood Adv. 2023. PMID: 37327122 Free PMC article.
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R. Long ME, et al. Among authors: helmig mason j. Blood Adv. 2024 Jan 9;8(1):150-163. doi: 10.1182/bloodadvances.2023010554. Blood Adv. 2024. PMID: 37782774 Free PMC article.